Condition 1: Acute myocardial infarction. Condition 2: Recurrent Myocardial Infarction. Acute myocardial infarction Subsequent myocardial infarction
Conditions
Interventions
Intervention 1: In Intracoronary arm (intervention), 180 micogram per Kg of patient's body weight administer, 2 bolus 10 minutes apart, first before pass the guidewire and second bolus after passing t
Treatment - Drugs
In Intracoronary arm (intervention), 180 micogram per Kg of patient's body weight administer, 2 bolus 10 minutes apart, first before pass the guidewire and second bolus after passing the guidewire, as
in IV arm (control), 180 microgram per Kg of patient's body weight of integrilin will be injected intravenously, 10 minutes apart, before and after passing the guidewire. Infusion of 2 microgram per k
Sponsors
QUMS Deputy for Research
Eligibility
Sex/Gender
All
Age
18 Years to 139 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: an acute coronary syndrome with the indication for cardiac catheterization being ST-elevation myocardial infarction; coronary artery disease with a visually estimated stenosis of at least 75% in at least 1 epicardial vessel suitable for stenting; age 18 years; negative pregnancy test in women of childbearing potential; informed consent for participation in the trial Exclusion Criteria: multivessel PCI at the time of the index procedure or planned PCI within 30 days of the index procedure; severe coronary calcification; unprotected left main stenosis > 50%; target lesion in a saphenous vein graft; acute ST-elevation myocardial infarction after a primary PCI strategy; previous stenting at the target lesion; target lesion in an occluded vessel; deep vein thrombosis; presence of an inferior vena cava filter; a contraindication to GP IIb/IIIa inhibitor therapy (Hypersensitivity to eptifibatide or any component of the product; active abnormal bleeding within the previous 30 days or a history of bleeding diathesis; history of stroke within 30 days or a history of hemorrhagic stroke; severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; current or planned administration of another parenteral GP IIb/IIIa inhibitor; dependency on hemodialysis).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TIMI Flow Grade. Timepoint: Before and After Primary PCI. Method of measurement: Antrograde Coronary Perfusion assessed by Coronary Angiograpgy.;TIMI Perfusion Grade. Timepoint: Before and After Primary PCI. Method of measurement: Antrograde Coronary Perfusion assessed by Coronary Angiograpgy based on TPG classification.;TIMI Frame Count. Timepoint: Before and After Primary PCI. Method of measurement: Angioraphic frame count of contrast from injection to filling the coronary artery which underwent Primary PCI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Bleeding Event. Timepoint: From Primary PCI to Patient Discharge. Method of measurement: Incidence of Bleeding event during hospitalization based on International Bleeding classification.;Change in Ejection Fraction. Timepoint: Before Primary PCI and 5 days after. Method of measurement: By Echocardiography.;ST Segment Elevation Resolution. Timepoint: Before Primary PCI and 60 minutes after. Method of measurement: Single-lead ST elevation (ST-E) recovery (percent reduction in ST-E from baseline to post-PCI ECG in the lead with maximum baseline ST-E).;Thrombocytopenia. Timepoint: Before Primary PCI and 3 hours after. Method of measurement: Reduction of Platelet in PBS over 50% or below 100000 per ml. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Esfandi
Qazvin University of Medical Sciences
Outcome results
None listed